Concordance Between CA-125 and RECIST Progression in Patients With BRCA-Mutated Relapsed Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Concordance Between CA-125 and RECIST Progression in Patients With Germline BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer Treated in the SOLO2 Trial With Olaparib as Maintenance Therapy After Response to Chemotherapy
Eur. J. Cancer 2020 Nov 01;139(xx)59-67, A Tjokrowidjaja, CK Lee, M Friedlander, V Gebski, L Gladieff, J Ledermann, R Penson, A Oza, J Korach, T Huzarski, L Manso, C Pisano, R Asher, SJ Lord, SI Kim, JY Lee, N Colombo, TW Park-Simon, K Fujiwara, G Sonke, I Vergote, JW Kim, E Pujade-LauraineFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.